


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(e))			Docket No. DI-4641 CONT	
In Re Application Of: Martis et al.				
Serial No. 09/955,248	Filing Date September 17, 2001	Examiner R. Keys	Group Art Unit 1621	
Title: BIOCHEMICALLY BALANCED PERITONEAL DIALYSIS SOLUTIONS				
Address to: Assistant Commissioner for Patents Washington, D.C. 20231				
<div style="text-align: center; margin-bottom: 10px;"> 37 CFR 1.97(b) </div> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <div style="text-align: center; margin-bottom: 10px;"> 37 CFR 1.97(c) </div> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e); </div> <div style="text-align: center; margin: 10px 0;"> OR </div> <div style="margin-left: 40px;"> <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p). </div>				




#7
5/15/02
Meren

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(e))

Docket No.
DI-4641 CONT

In Re Application: Martis et al.



Serial No.

09/955,248

Filing Date

September 17, 2001

Examiner

R. Keys

Group Art Unit

1621

BIOCHEMICALLY BALANCED PERITONEAL DIALYSIS SOLUTIONS**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited
4/30/2002 with the U.S. Postal Service
as first class mail under 37 C.F.R. 1.8 and is
addressed to the Assistant Commissioner for Patents,
Washington/D.C. 20231.

Signature of Person Mailing Correspondence

Robert Buccieri

Typed or Printed Name of Person Mailing Certificate


*This certificate may only be used if paying by
deposit account.

Signature

Dated: April 30, 2002

Robert M. Barrett (30,142)
ATTORNEYS FOR APPLICANT
Bell, Boyd & Lloyd LLC
P.O. Box 1135
Chicago, Illinois 60690-1135

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Martis et al.
Appl. No.: 09/955,248
Filed: September 17, 2001
Title: BIOCHEMICALLY BALANCED PERITONEAL DIALYSIS SOLUTIONS
Art Unit: 1621
Examiner: R. Keys
Docket No.: DI-4641 CONT

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, copies of which can be found in the parent, application no. 08/421,020, filed on April 12, 1995, be made during the course of examination of the above-identified application for United States patent.

U.S. PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Inventor</u>
4,396,383	8/2/1983	Hart
4,465,488	8/14/1984	Richmond et al.
4,584,176	4/22/1986	Oliver et al.
4,630,727	12/3/1986	Feriani et al.
4,663,166	5/5/1987	Veech
4,756,838	7/12/1988	Veltman
4,863,714	9/5/1989	Sovak et al.
4,879,280	11/7/1989	Seyffart et al.
4,959,175	9/25/1990	Yatzidis
5,039,609	8/13/1991	Klein
5,141,492	8/25/1992	Dadson et al.
5,383,324	1/24/1995	Segers et al.
5,423,421	6/13/1995	Inoue et al.
5,431,496	7/11/1995	Balteau et al.
5,462,526	10/31/1995	Barney et al.

5,509,898	4/23/1996	Isono et al.
5,536,469	7/16/1996	Jonsson et al.
5,560,403	10/1/1996	Balteau et al.
5,610,170	3/11/1997	Inoue et al.
5,706,937	1/13/1998	Futagawa et al.
5,853,388	12/29/1998	Semel
5,871,477	2/16/1999	Isono et al.
5,945,129	8/31/1999	Knerr et al.

FOREIGN PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Country</u>
56164113	17/12/1981	Japan
0 083 360	10/7/1981	Europe
0 165 933 B1	2/1/1986	Europe
WO 86/03407	19/6/1986	PCT
WO 87/03809	2/7/1987	PCT
0 249 667 B1	23/12/1987	Europe
0 277 868	8/10/1988	Europe
0 278 100	17/6/1988	Europe
0 209 607	20/12/1989	Europe
0 399 549	28/11/1990	Europe (Including Translation)
2304026	17/12/1990	Japan
0 439 061 B1	31/7/1991	Europe
3195561	27/8/1991	Japan
WO 91/18610	12/12/1991	PCT
5105633	27/4/1993	Japan
6105905	19/4/1994	Japan
0 613 688 A1	7/9/1994	Europe
0 647 145 B1	12/4/1995	Europe
WO 95/19778	27/7/1995	PCT
7252137	3/10/1995	Japan
WO 96/01118	18/1/1996	PCT
8131542	28/5/1996	Japan

8164199	25/6/1996	Japan
WO 97/05851	20/2/1997	PCT
9087182	31/3/1997	Japan
9110703	28/4/1997	Japan
0 776 649 A2	4/6/1997	Europe
9301875	25/11/1997	Japan
2 735 099	13/3/1998	France
98/10733	19/3/1998	PCT
10201821	4/8/1998	Japan
11004872	12/1/1999	Japan
99/01144	14/1/1999	PCT
11-9659	19/1/1999	Japan (Laid-Open Publication Including Translation)
11019178	26/1/1999	Japan
99/09953	4/3/1999	PCT (Abstract Only)
19748290	6/5/1999	Germany
99/22746	14/5/1999	PCT
99/27885	10/6/1999	PCT
0 935 967	18/8/1999	Europe (Including Translation)
0 845 970	26/1/2000	Europe

OTHER DOCUMENTS

American Society for Artificial Internal Organs, 1994 Abstracts.

Boen ST, *A Clinical Study of Factors Governing its Effectiveness*, Peritoneal Dialysis, p. 76, Van Gorcum & Co., Assen, The Netherlands (1959).

Faller et al., "Loss of Ultrafiltration in Continuous Ambulatory Peritoneal Dialysis: A Role for Acetate", Peritoneal Dialysis Bulletin, January-March 1984, pp. 10-13.

Feriani et al., *Bicarbonate Solutions for Peritoneal Dialysis: A Reality*, Int J Artif Organs 8:57-58 (1985).

Ing et al., *Preparation of Bicarbonate-Containing Dialysate for Peritoneal Dialysis*, Int J Artif Organs, Vol. 6, No. 4, pp. 217-218 (1983).

Ing et al., *Lactate-Containing Peritoneal Dialysis Solutions*, Int J Artif Organs, Vol. 16, No. 10, pp. 688-693 (1993).

The Merck Index, 12th Ed., Merck Research Laboratories, Whitehouse Station, NJ, p. 1472 (1996).

Murphey et al., *Use of an Artificial Kidney*, J. Lab. Clin. Med., Volume 40, pp. 436-444 (1952).

Odel HM et al., *Peritoneal Lavage as an Effective Means of Extrarenal Excretion. A Clinical Appraisal*, American Journal of Medicine, Vol. 9, 63-88 (1950).

Schambye et al., *The Cytotoxicity of Continuous Ambulatory Peritoneal Dialysis Solutions with Different Bicarbonate/Lactate Ratios*, Peritoneal Dialysis International, Vol. 13, Suppl. 2; Oct. 1-4/92, pp. S116-S118.

Simonsen et al., *Less Infusion Pain and Elevated Level of Cancer Antigen 125 by the Use of a New and More Biocompatible PD Fluid*, Advances in Peritoneal Dialysis, Vol. 12, pp. 156-160 (1996).


T.S. Ing. et al., *Bicarbonate-Buffered Peritoneal Dialysis*, The International Journal of Artificial Organs, Volume 8, No. 3, p. 121-124 (1985).

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY



Robert M. Barrett
Reg. No. 30,142
P.O. Box 1135
Chicago, Illinois 60690-1135
Phone: (312) 807-4204